Last reviewed · How we verify
Three-dose regimen of commercialized IPV — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
Three-dose regimen of commercialized IPV (Three-dose regimen of commercialized IPV) — Jiangsu Province Centers for Disease Control and Prevention.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Three-dose regimen of commercialized IPV TARGET | Three-dose regimen of commercialized IPV | Jiangsu Province Centers for Disease Control and Prevention | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Three-dose regimen of commercialized IPV CI watch — RSS
- Three-dose regimen of commercialized IPV CI watch — Atom
- Three-dose regimen of commercialized IPV CI watch — JSON
- Three-dose regimen of commercialized IPV alone — RSS
Cite this brief
Drug Landscape (2026). Three-dose regimen of commercialized IPV — Competitive Intelligence Brief. https://druglandscape.com/ci/three-dose-regimen-of-commercialized-ipv. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab